We have located links that may give you full text access.
Comparative Study
English Abstract
Journal Article
[Virological and immunological studies on inapparent Epstein-Barr virus infection in healthy individuals: in comparison to immunosuppressed patients and patients with infectious mononucleosis].
The inapparent Epstein-Barr virus (EBV) infection status in healthy Japanese subjects was assessed for their EBV seroepidemiology, oral EBV excretion, and EBV-specific cellular immunity, in comparison with immunosuppressed patients and patients with infectious mononucleosis. The seroepidemiologic data of 1,086 healthy donors indicate that EBV infects the vast majority of young children by 2-3 years of age and the viral persistence follows in nearly all adults throughout life. EBV antibody titers were significantly higher in both early and late ages. When 35 seropositive healthy persons were monthly assessed for their oral EBV excretion during 1 year period, 25% shed the virus consistently, 50% every other time, and the remaining 25% occasionally. EBV was shed more frequently from 17 immunosuppressed patients and all times from 15 cases of infectious mononucleosis, in the acute and convalescent phases and also during 1 year after healing. There was a tendency that high frequency EBV shedders had high titer EBV in the mouth. In infected healthy persons, EBV-specific killer T cells were well functioning throughout life; however, the killer T cell activity were significantly low in immunosuppressed patients. The killer T cell activity first developed in infectious mononucleosis 1 week after the onset and reached the same level as in seropositive healthy persons, by 4 weeks. These findings indicate that EBV-specific cellular immunity plays an important role in the establishment and maintenance of the inapparent EBV infection in humans.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app